ArticleTzu chi medical journal
Stereotactic body radiotherapy for inoperable primary and recurrent cholangiocarcinoma: A single-institution retrospective analysis.
Article in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Cholangiocarcinoma is a rare and aggressive malignancy with a poor prognosis, particularly in patients who are not candidates for surgical resection. Stereotactic body radiotherapy (SBRT) combines high-dose radiation delivery with meticulous spatial accuracy, allowing for effective local control in a variety of solid tumors. However, clinical data supporting the use of SBRT in cholangiocarcinoma are limited, and this study aimed to investigate the feasibility, safety, and oncologic outcomes of SBRT. Materials and Methods: We retrospectively analyzed 21 consecutive patients with unresectable cholangiocarcinoma who received SBRT between May 2012 and February 2024 at our institution. Eligible patients had no prior liver- or biliary-directed radiotherapy and no distant metastases. Target delineation was performed using four-dimensional computed tomography or breath-hold techniques. SBRT doses ranged from 50 to 60 Gy in 7-10 fractions. Results: The cohort included 16 men and 5 women with a median age of 76 years (range: 58-86). Thirteen patients (62%) had previously undergone surgery and were treated for recurrent disease. At a median follow-up of 9.5 months, the 1-year local control rate was 77.2%. For the entire cohort, the 1-year overall survival and progression-free survival rates were 47.5% (95% confidence interval [CI]: 24.5%-67.4%) and 32.4% (95% CI: 13.4%-53.2%), respectively. Three patients (14.2%) experienced Grade 3 or higher adverse events, consisting of one gastric ulcer and two instances of biliary stricture. Conclusion: SBRT may represent a feasible treatment approach for patients with inoperable cholangiocarcinoma, showing encouraging local control with acceptable toxicity in this small cohort. However, given the study's limitations, these findings should be regarded as exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.